Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (251)	7/6/2003 4:56:48 PM
From: Miljenko Zuanic	Read Replies (1) of 590

<<Am I right in thinking that the early stage pipeline is pretty thin compared with (eg) DNA ?>> Yes, I think that they are bit short with biologic and biologic targets, regardless that from IMNX they expanded into cancer-immunology. Now, they are expanding into small molecules arena, but this is early and will take time to generate something of the substance. ABGX targets pipeline (from CRGN and LEXG collaborations) will and is in synergy with their business model. Nonetheless, I will prefer that ABGX stay independent and growth organically. <<I still cannot see why they were in such a hurry to take over HuMax-IL15 from Genmab.>> Genmab is EU company and by early contract IL-15 control was shared between companies. Difficult for AMGN, as they prefer to have solely control, like pharma. Control not only over clinical development, but as well over generated knowledge over target-candidate relations. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next